• About Us
  • International Patients
  • Pay Online
  • Careers
  • Enquire Now
  • Feedback
  • Location Image
icon
×
Best Medical and Hemato Oncologist in Bhubaneswar

Dr. Goutam Santosh Panda

Senior Consultant Medical & Hemato Oncology

Speciality

Medical Oncology

Qualification

MBBS, MD, DM (Medical Oncology)

Experience

10 Years

Location

CARE Hospitals, Bhubaneswar

Refer Doctor

Best Medical and Hemato Oncologist in Bhubaneswar

Field(s) of Expertise

  • Immunotherapy
  • Targeted therapy 
  • Precision Medicine 
  • Hormone therapy
  • Chemotherapy including intensive chemotherapy 
  • Bone marrow transplant 

Publications

  • Agarwal JP, Krishnatry R, Panda G, et al. An audit for radiotherapy planning and treatment errors from a low-middle-income country centre. Clin Oncol (R Coll Radiol). 2019;31(1).
  • Panda GS, Bajpai J, Chandrasekharan A, et al. Adolescent-adult nonmetastatic Ewing sarcoma—experience from a large developing country. Pediatr Blood Cancer. 2021;68. doi:10.1002/pbc.29081.
  • Panda G, Kalra B, Rishi A, Khanna N, Kakoti S, Sridhar E, et al. Long-term clinical outcomes and sequelae of therapy in early-stage orbital mucosa-associated lymphoid tissue lymphoma. Clin Lymphoma Myeloma Leuk. 2021. doi:10.1016/j.clml.2021.12.013.
  • Panda GS, Noronha V, Shetty O, et al. FGFR alterations in head-and-neck cancer. Cancer Res Stat Treat. 2021;4(4):737.
  • Noronha V, Abraham G, Bondili SK, Rajpurohit A, Menon RP, Gattani S, et al. COVID-19 vaccine uptake and vaccine hesitancy in Indian patients with cancer: a questionnaire-based survey. Cancer Res Stat Treat. 2021;4(2):211.
  • Shenoy R, Panda G, Bonda VNA, Sengar M, Thorat J, Jain H. Feasibility of delivering high-dose methotrexate in adolescent and adult ALL patients: a retrospective study. Indian J Hematol Blood Transfus. 2021. doi:10.1007/s12288-021-01502-0.
  • Panda G, Chandrasekharan A, Das S, Bhargava P, Srinivas S, Laskar S, et al. Outcomes of Ewing sarcoma in adults over 40 years of age from a low-middle income country. Ecancermedicalscience. 2022;16:1361. doi:10.3332/ecancer.2022.1361.
  • Panda GS, Noronha V, Yadav S, et al. Small cell carcinoma of the oesophagus: experience of an Indian tertiary cancer centre. Ecancermedicalscience. 2022;16:1393. doi:10.3332/ecancer.2022.1393.
  • Panda GS, Noronha V, Shah D, et al. Treatment pattern and outcomes in de novo T790M-mutated non-small cell lung cancer. Ecancermedicalscience. 2022;16:1385. doi:10.3332/ecancer.2022.1385.
  • Panda GS, Noronha V, Shetty O, et al. EGFR exon 20 insertion in non-small cell lung cancer. Cancer Res Stat Treat. 2022;5:122.
  • Panda GS, Noronha V, Shetty O, et al. ROS1-positive non-small-cell lung cancer. Cancer Res Stat Treat. 2022;5(3):544.
  • Panda GS, Noronha V, Patil VM, Joshi AP, Menon NS, Singh AC, et al. Demographics, treatment patterns and clinical outcomes in ROS1-positive non-small cell lung cancer: a referral tertiary cancer centre experience from a low-middle income country. Ann Oncol. 2022;33(Suppl 7). doi:10.1016/j.annonc.2022.10.428.
  • Noronha V, Goud S, Sharma R, More SB, Yadav A, Nakti D, et al. A randomized trial of patient navigation with symptom-monitoring in advanced lung cancer. J Clin Oncol. 2023;41(17 Suppl). doi:10.1200/JCO.2023.41.17_suppl.LBA1545.
  • Chugh S, Panda G, Mokal S, Jain H, Bagal B, Khanna N, et al. Long-term clinical outcomes of combined modality therapy for advanced-stage Hodgkin lymphoma in the PET era: a retrospective study. Indian J Med Res. 2024;159(2):193-205.
  • Panda GS, Noronha V, Patil VM, Joshi A, Menon N, Kumar R, et al. Clinical outcomes of ROS1-positive non-small cell lung cancer with limited access to ROS1-tyrosine kinase inhibitors (TKIs): experience from an Indian tertiary referral centre. Ecancermedicalscience. 2024;18:1654. doi:10.3332/ecancer.2024.1654.
  • Bajpai J, Sarkar L, Rath S, Chandrasekharan A, Panda G, Jakar D, et al. Ten-year follow-up of outcomes, patterns of care, and psychosocial burden in adolescent and young adult (AYA) patients with bone sarcomas from a large cohort in a low-income and middle-income country (LMIC). Cancer. 2024. doi:10.1002/cncr.35547.
  • Kumar A, Kapoor A, Noronha V, Patil VM, Joshi A, Menon N, Janu A, Mahajan A, Rajendra A, Agarawal A, Khaddar S, Rajpurohit A, Kashyap L, Srikant A, Panda G, Kota KK, Talreja V, Prabhash K. Efficacy and safety of low-dose nivolumab in treatment of advanced solid tumors: a retrospective audit from resource-constrained settings. South Asian J Cancer. 2025;14(1):70-76. doi:10.1055/s-0044-1788649.
  • Bajpai J, Sarkar L, Rath S, Pawar A, Chandrasekharan A, Panda G, et al. Prognostic modeling for bone sarcomas based on a large prospective cohort from a tertiary care cancer center in India. JCO Glob Oncol. 2025;11.
  • Bhargava P, Ramaswamy A, Panda G, et al. Outcomes of gastrointestinal tumours in the tyrosine kinase inhibitor era: 15 years of experience from a single tertiary care centre in India. Ann Oncol. 2019;30(Suppl 4).
  • Panda GS, Bajpai J, Dandekar S, et al. 1643P Demographics and outcomes of non-metastatic Ewing's sarcoma (ES) from a low-middle income country (LMIC). Ann Oncol. 2020;31(Suppl 4).

Education

  • 2021- Passed DM (Medical Oncology) -Tata Memorial Hospital, Mumbai 
  • 2016- Passed MD- Tata Memorial Hospital, Mumbai 
  • 2011- Passed MBBS- N.R.S. Medical College and Hospital, Kolkata, West Bengal 
  • 2004- Passed H.S.E -Khallikote Junior College, Berhampur, Odisha 
  • 2002- Passed HSCE- Saraswati Vidya Mandir, Neelakantha Nagar, Berhampur, Odisha

Fellowship/Membership

  • ESMO ( European Society of Medical Oncology)
  • ASCO( American Society of Clinical Oncology)

Past Positions

  • Asst Prof( Ad hoc), Medical Oncology, TMH Mumbai 
  • Consultant Medical & Hemato Oncologist, AOI, Nagpur 
  • Consultant Medical & Hemato Oncologist, Utkal Hospital, Bhubaneswar
  • Consultant Medical & Hemato Oncologist, Bagchi Sri Shankara Cancer Centre & Research Institute , Bhubaneswar

Frequently Asked Questions

Still Have a Question?

If you cannot find answers to your queries, please fill out the enquiry form or call the number below. We will contact you shortly.

volume control phone icon +91-40-68106529